Search Results - "CIRRINCIONE, Constance" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

by HUGHES, Kevin S, SCHNAPER, Lauren A, WOOD, William C, BELLON, Jennifer R, CIRRINCIONE, Constance T, BERRY, Donald A, MCCORMICK, Beryl, MUSS, Hyman B, SMITH, Barbara L, HUDIS, Clifford A, WINER, Eric P
Published in Journal of clinical oncology (01.07.2013)

Get full text

Journal Article

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

by Sikov, William M, Berry, Donald A, Perou, Charles M, Singh, Baljit, Cirrincione, Constance T, Tolaney, Sara M, Kuzma, Charles S, Pluard, Timothy J, Somlo, George, Port, Elisa R, Golshan, Mehra, Bellon, Jennifer R, Collyar, Deborah, Hahn, Olwen M, Carey, Lisa A, Hudis, Clifford A, Winer, Eric P
Published in Journal of clinical oncology (01.01.2015)

Get full text

Journal Article

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)

by Golshan, Mehra, Cirrincione, Constance T, Sikov, William M, Berry, Donald A, Jasinski, Sara, Weisberg, Tracey F, Somlo, George, Hudis, Clifford, Winer, Eric, Ollila, David W
Published in Annals of surgery (01.09.2015)

Get more information

Journal Article

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

by Carey, Lisa A, Berry, Donald A, Cirrincione, Constance T, Barry, William T, Pitcher, Brandelyn N, Harris, Lyndsay N, Ollila, David W, Krop, Ian E, Henry, Norah Lynn, Weckstein, Douglas J, Anders, Carey K, Singh, Baljit, Hoadley, Katherine A, Iglesia, Michael, Cheang, Maggie Chon U, Perou, Charles M, Winer, Eric P, Hudis, Clifford A
Published in Journal of clinical oncology (20.02.2016)

Get full text

Journal Article

Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

by HURRIA, Arti, CIRRINCIONE, Constance T, KIRSHNER, Jeffrey, TOGAWA, Kayo, HANSEN, Kurt, KATHERIA, Vani, STONE, Richard, GALINSKY, Ilene, POSTIGLIONE, John, JAY COHEN, Harvey, MUSS, Hyman B, KORNBLITH, Alice B, BARRY, William, ARTZ, Andrew S, SCHMIEDER, Linda, ANSARI, Rafat, TEW, William P, WECKSTEIN, Douglas
Published in Journal of clinical oncology (01.04.2011)

Get full text

Journal Article

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

by Dickler, Maura N, Barry, William T, Cirrincione, Constance T, Ellis, Matthew J, Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S, Lake, Diana E, Hahn, Olwen, Schneider, Bryan P, Tripathy, Debasish, Carey, Lisa A, Winer, Eric P, Hudis, Clifford A
Published in Journal of clinical oncology (01.08.2016)

Get full text

Journal Article

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

by SEIDMAN, Andrew D, BERRY, Donald, UNGARO, Peter, NORTON, Larry, WINER, Eric, HUDIS, Clifford, CIRRINCIONE, Constance, HARRIS, Lyndsay, MUSS, Hyman, KELLY MARCOM, P, GIPSON, Grandella, BURSTEIN, Harold, LAKE, Diana, SHAPIRO, Charles L
Published in Journal of clinical oncology (01.04.2008)

Get full text

Journal Article

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

by Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Carey, Lisa A., Berry, Donald A., Overmoyer, Beth, Henry, Nora L., Somlo, George, Port, Elisa, Burstein, Harold J., Hudis, Clifford, Winer, Eric, Ollila, David W.
Published in Breast cancer research and treatment (01.11.2016)

Get full text

Journal Article

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)

by Burstein, Harold J, Cirrincione, Constance T, Barry, William T, Chew, Helen K, Tolaney, Sara M, Lake, Diana E, Ma, Cynthia, Blackwell, Kimberly L, Winer, Eric P, Hudis, Clifford A
Published in Journal of clinical oncology (10.12.2014)

Get full text

Journal Article

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

by Muss, Hyman B, Polley, Mei-Yin C, Berry, Donald A, Liu, Heshan, Cirrincione, Constance T, Theodoulou, Maria, Mauer, Ann M, Kornblith, Alice B, Partridge, Ann H, Dressler, Lynn G, Cohen, Harvey J, Kartcheske, Patricia A, Perez, Edith A, Wolff, Antonio C, Gralow, Julie R, Burstein, Harold J, Mahmood, Ahmad A, Sutton, Linda M, Magrinat, Gustav, Parker, Barbara A, Hart, Ronald D, Grenier, Debjani, Hurria, Arti, Jatoi, Aminah, Norton, Larry, Hudis, Clifford A, Winer, Eric P, Carey, Lisa
Published in Journal of clinical oncology (10.09.2019)

Get full text

Journal Article

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

by Muss, Hyman B, Berry, Donald A, Cirrincione, Constance T, Theodoulou, Maria, Mauer, Ann M, Kornblith, Alice B, Partridge, Ann H, Dressler, Lynn G, Cohen, Harvey J, Becker, Heather P, Kartcheske, Patricia A, Wheeler, Judith D, Perez, Edith A, Wolff, Antonio C, Gralow, Julie R, Burstein, Harold J, Mahmood, Ahmad A, Magrinat, Gustav, Parker, Barbara A, Hart, Ronald D, Grenier, Debjani, Norton, Larry, Hudis, Clifford A, Winer, Eric P
Published in The New England journal of medicine (14.05.2009)

Get full text

Journal Article

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

by Ligibel, Jennifer A, Cirrincione, Constance T, Liu, Minetta, Citron, Marc, Ingle, James N, Gradishar, William, Martino, Silvana, Sikov, William, Michaelson, Richard, Mardis, Elaine, Perou, Charles M, Ellis, Matthew, Winer, Eric, Hudis, Clifford A, Berry, Donald, Barry, William T
Published in JNCI : Journal of the National Cancer Institute (01.09.2015)

Get full text

Journal Article

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

by Shulman, Lawrence N, Cirrincione, Constance T, Berry, Donald A, Becker, Heather P, Perez, Edith A, O'Regan, Ruth, Martino, Silvana, Atkins, James N, Mayer, Erica, Schneider, Charles J, Kimmick, Gretchen, Norton, Larry, Muss, Hyman, Winer, Eric P, Hudis, Clifford
Published in Journal of clinical oncology (20.11.2012)

Get full text

Journal Article

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

by SHULMAN, Lawrence N, BERRY, Donald A, BURSTEIN, Harold J, NORTON, Larry, MUSS, Hyman, HUDIS, Clifford A, WINER, Eric P, CIRRINCIONE, Constance T, BECKER, Heather P, PEREZ, Edith A, O'REGAN, Ruth, MARTINO, Silvana, SHAPIRO, Charles L, SCHNEIDER, Charles J, KIMMICK, Gretchen
Published in Journal of clinical oncology (01.08.2014)

Get full text

Journal Article

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

by MUSS, Hyman B, BERRY, Donald A, CIRRINCIONE, Constance, BUDMAN, Daniel R, HENDERSON, I. Craig, CITRON, Marc L, NORTON, Larry, WINER, Eric P, HUDIS, Clifford A
Published in Journal of clinical oncology (20.08.2007)

Get full text

Journal Article

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907

by Lichtman, Stuart M, Cirrincione, Constance T, Hurria, Arti, Jatoi, Aminah, Theodoulou, Maria, Wolff, Antonio C, Gralow, Julie, Morganstern, Daniel E, Magrinat, Gustav, Cohen, Harvey Jay, Muss, Hyman B
Published in Journal of clinical oncology (01.03.2016)

Get full text

Journal Article

Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

by Ollila, David W., MD, FACS, Cirrincione, Constance T., MS, Berry, Donald A., PhD, Carey, Lisa A., MD, Sikov, William M., MD, Hudis, Clifford A., MD, Winer, Eric P., MD, Golshan, Mehra, MD, FACS
Published in Journal of the American College of Surgeons (01.04.2017)

Get full text

Journal Article

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease

by Cardona, Diana M, Detweiler, Claire J, Shealy, Michael J, Sung, Anthony D, Wild, Daniel M, Poleski, Martin H, Balmadrid, Bryan L, Cirrincione, Constance T, Howell, David N, Sullivan, Keith M
Published in Archives of pathology & laboratory medicine (1976) (01.09.2018)

Get full text

Journal Article

Reply to V. Amoroso et al

Reply to V. Amoroso et al

by Shulman, Lawrence N, Berry, Donald A, Cirrincione, Constance T, Hudis, Clifford A, Winer, Eric P
Published in Journal of clinical oncology (20.01.2015)

Get full text

Journal Article

The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)

The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)

by Morrison, Vicki A., McCall, Linda, Muss, Hyman B., Jatoi, Aminah, Cohen, Harvey J., Cirrincione, Constance T., Ligibel, Jennifer A., Lafky, Jacqueline M., Hurria, Arti
Published in Journal of geriatric oncology (01.05.2018)

Get full text

Journal Article

1
2
3
4
5
6
Next
[6]